Ramírez-Mejía MM, Teschke R, Méndez-Sánchez N. Open questions on how metabolic dysfunction-associated steatotic liver disease shapes the course of drug-induced liver injury. World J Hepatol 2025; 17(5): 105072 [DOI: 10.4254/wjh.v17.i5.105072]
Corresponding Author of This Article
Nahum Méndez-Sánchez, MD, PhD, Professor, Liver Research Unit, Medica Sur Clinic & Foundation, 150 Puente de Piedra, Mexico City 14050, Mexico. nmendez@medicasur.org.mx
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. May 27, 2025; 17(5): 105072 Published online May 27, 2025. doi: 10.4254/wjh.v17.i5.105072
Open questions on how metabolic dysfunction-associated steatotic liver disease shapes the course of drug-induced liver injury
Mariana M Ramírez-Mejía, Rolf Teschke, Nahum Méndez-Sánchez
Mariana M Ramírez-Mejía, Plan of Combined Studies in Medicine, Faculty of Medicine, National Autonomous University of Mexico, Mexico City 04360, Mexico
Mariana M Ramírez-Mejía, Nahum Méndez-Sánchez, Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City 14050, Mexico
Rolf Teschke, Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Academic Teaching Hospital of the Medical Faculty, Goethe University Frankfurt, Hanau 63450, Hesse, Germany
Author contributions: Ramírez-Mejía MM and Méndez-Sánchez N designed the overall concept and the outline of the manuscript; Ramírez-Mejía MM, Teschke R, and Méndez-Sánchez N contributed to the discussion and design of the manuscript, the writing and editing of the manuscript, the illustrations, and the review of the literature.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nahum Méndez-Sánchez, MD, PhD, Professor, Liver Research Unit, Medica Sur Clinic & Foundation, 150 Puente de Piedra, Mexico City 14050, Mexico. nmendez@medicasur.org.mx
Received: January 11, 2025 Revised: February 27, 2025 Accepted: March 24, 2025 Published online: May 27, 2025 Processing time: 137 Days and 4.9 Hours
Core Tip
Core Tip: This article reviews the study by Zhao et al on the interaction between metabolic dysfunction-associated steatotic liver disease and drug-induced liver injury. This study highlights distinct clinical patterns in patients with metabolic dysfunction-associated steatotic liver disease and drug-induced liver injury, such as metabolic dysregulation (elevated triglycerides, cholesterol and insulin) and immune activation (increased levels of interleukin-4 and complement C3). The use of the updated Roussel Uclaf Causality Assessment Method strengthens the assessment of causality, emphasizing the need for tailored diagnostic approaches and therapeutic strategies. This work paves the way for prospective studies and biomarker discovery to improve patient outcomes at the intersection of these conditions.
